Astellas gathers scattered cell and gene therapy, BD units in new $70M South San Francisco hub
Bringing all its West Coast-based units under one roof, Astellas has unveiled plans to pour $70 million into a new biotech campus in South San Francisco.
With cell and gene therapies as the dominant theme, the Japanese pharma spotlighted Astellas Gene Therapies and Xyphos Biosciences, which is developing cell therapies for solid tumors, as the two big subsidiaries that will occupy the space. Those working in the business development team and the Rx+ Business Accelerator are also set to move in with them.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.